Oculis to Participate at Upcoming April Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL

6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Get Alerts OCS Hot Sheet

Price: $12.94 +0.94%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’s management will be attending and presenting at the following upcoming investor conferences:

Needham Annual Virtual Healthcare ConferenceFormat: Corporate presentation Presenter: Riad Sherif, MD, Chief Executive OfficerPresentation date and time: April 11, 2024 at 8:00 am EDT Location: VirtualWebcast: here

Van Lanschot Kempen Life Sciences ConferenceDate: April 16-17, 2024Location: Amsterdam, the Netherlands

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative to request meetings.

About Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’s highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Oculis’s goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis ContactsMs. Sylvia Cheung, CFO[email protected]

Investor & Media Relations LifeSci AdvisorsCorey Davis, Ph.D.[email protected]1-212-915-2577